Achilles Therapeutics plc (ACHL) Financials

ACHL Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 175.3 million 21.9 million
2023-06-30 197.9 million 24.1 million
2023-03-31 207.6 million 22.5 million
2022-12-31 220.4 million 23.3 million

ACHL Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 1.0 million ?
2023-06-30 -17946 1701
2023-03-31 -18307 1652
2022-12-31 -21.8 million 1.7 million

ACHL Net Income

No data available :(

ACHL Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 140.1 million - 7.4 million
2023-06-30 143.7 million - 8.6 million
2023-03-31 158.5 million - 7.6 million
2022-12-31 173.3 million - 8.6 million

ACHL Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 40.1 million
2023-06-30 39.9 million
2023-03-31 39.7 million
2022-12-31 39.3 million

ACHL Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 61383 14.7 million 4.4 million -
2023-06-30 537 13.8 million 4.3 million -
2023-03-31 454 13.9 million 4.7 million -
2022-12-31 2.1 million 18.9 million 4.0 million -

ACHL Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 1.2 million
2023-06-30 - 1.3 million
2023-03-31 - -
2022-12-31 - 837227

ACHL

Price: $0.78

52 week price:
0.74
1.76

Earnings Per Share: -1.74 USD

P/E Ratio: -0.50

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 354400

Market Capitalization: 35.3 million

Links: